Modality
Radioligand
MOA
PD-L1i
Target
MET
Pathway
JAK/STAT
EoEPsoriasis
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
Aug 2019
→ Nov 2031
Phase 2Current
NCT05674736
2,989 pts·EoE
2020-06→2031-11·Terminated
NCT07750318
2,117 pts·EoE
2019-08→2025-05·Completed
5,106 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-1211mo agoPh3 Readout· EoE
2031-11-215.6y awayPh3 Readout· EoE
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Complet…
P2/3
Termina…
Catalysts
Ph3 Readout
2025-05-12 · 11mo ago
EoE
Ph3 Readout
2031-11-21 · 5.6y away
EoE
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05674736 | Phase 2/3 | EoE | Terminated | 2989 | CfB |
| NCT07750318 | Phase 2/3 | EoE | Completed | 2117 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |